CN102697846A - 愈风宁心包衣滴丸及其制备方法 - Google Patents
愈风宁心包衣滴丸及其制备方法 Download PDFInfo
- Publication number
- CN102697846A CN102697846A CN2012101917733A CN201210191773A CN102697846A CN 102697846 A CN102697846 A CN 102697846A CN 2012101917733 A CN2012101917733 A CN 2012101917733A CN 201210191773 A CN201210191773 A CN 201210191773A CN 102697846 A CN102697846 A CN 102697846A
- Authority
- CN
- China
- Prior art keywords
- drop pill
- yufengningxin
- radix puerariae
- coating
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 112
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 238000000576 coating method Methods 0.000 claims abstract description 54
- 239000011248 coating agent Substances 0.000 claims abstract description 48
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 30
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 28
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 27
- 239000000284 extract Substances 0.000 claims abstract description 26
- 239000007888 film coating Substances 0.000 claims abstract description 24
- 238000009501 film coating Methods 0.000 claims abstract description 24
- 229930003944 flavone Natural products 0.000 claims abstract description 8
- 235000011949 flavones Nutrition 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 239000000243 solution Substances 0.000 claims description 36
- 239000002826 coolant Substances 0.000 claims description 24
- 230000002572 peristaltic effect Effects 0.000 claims description 16
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 13
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 210000002784 stomach Anatomy 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 239000007921 spray Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 150000002213 flavones Chemical class 0.000 claims description 7
- 239000012567 medical material Substances 0.000 claims description 7
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000013459 approach Methods 0.000 claims description 5
- 238000007664 blowing Methods 0.000 claims description 5
- 238000002386 leaching Methods 0.000 claims description 5
- 239000000155 melt Substances 0.000 claims description 5
- 238000007711 solidification Methods 0.000 claims description 5
- 230000008023 solidification Effects 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 16
- 230000008569 process Effects 0.000 abstract description 9
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 235000010575 Pueraria lobata Nutrition 0.000 abstract description 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 2
- 206010061216 Infarction Diseases 0.000 abstract description 2
- 206010039966 Senile dementia Diseases 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000007574 infarction Effects 0.000 abstract description 2
- 244000046146 Pueraria lobata Species 0.000 abstract 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract 1
- 150000002212 flavone derivatives Chemical class 0.000 abstract 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 abstract 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 14
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 8
- 239000013558 reference substance Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000008118 PEG 6000 Substances 0.000 description 5
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 5
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 241001295925 Gegenes Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 2
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000002333 glycines Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000011020 pilot scale process Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 101710094902 Legumin Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009512 pharmaceutical packaging Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210191773 CN102697846B (zh) | 2012-06-12 | 2012-06-12 | 愈风宁心包衣滴丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201210191773 CN102697846B (zh) | 2012-06-12 | 2012-06-12 | 愈风宁心包衣滴丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102697846A true CN102697846A (zh) | 2012-10-03 |
CN102697846B CN102697846B (zh) | 2013-08-28 |
Family
ID=46891093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201210191773 Active CN102697846B (zh) | 2012-06-12 | 2012-06-12 | 愈风宁心包衣滴丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102697846B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800428A (zh) * | 2012-11-15 | 2014-05-21 | 吉林吉春制药股份有限公司 | 一种治疗高血压病阴虚阳亢症以及冠心病的药物及其制备方法 |
CN107753522A (zh) * | 2017-10-24 | 2018-03-06 | 吉林农业科技学院 | 林蛙油包衣滴丸的制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1569068A (zh) * | 2003-07-22 | 2005-01-26 | 周美华 | 愈风宁心微丸的制备方法 |
CN1768779A (zh) * | 2005-10-25 | 2006-05-10 | 北京创立科创医药技术开发有限公司 | 愈风宁心软胶囊及其制备 |
CN1823747A (zh) * | 2005-02-25 | 2006-08-30 | 山东绿叶天然药物研究开发有限公司 | 丹皮酚薄膜衣滴丸及其制备方法 |
CN101474218A (zh) * | 2008-12-31 | 2009-07-08 | 四川禾邦阳光制药股份有限公司 | 一种穿心莲滴丸及其制备方法 |
-
2012
- 2012-06-12 CN CN 201210191773 patent/CN102697846B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1569068A (zh) * | 2003-07-22 | 2005-01-26 | 周美华 | 愈风宁心微丸的制备方法 |
CN1823747A (zh) * | 2005-02-25 | 2006-08-30 | 山东绿叶天然药物研究开发有限公司 | 丹皮酚薄膜衣滴丸及其制备方法 |
CN1768779A (zh) * | 2005-10-25 | 2006-05-10 | 北京创立科创医药技术开发有限公司 | 愈风宁心软胶囊及其制备 |
CN101474218A (zh) * | 2008-12-31 | 2009-07-08 | 四川禾邦阳光制药股份有限公司 | 一种穿心莲滴丸及其制备方法 |
Non-Patent Citations (1)
Title |
---|
李月等: "愈风宁心滴丸的制备工艺研究", 《化学与生物工程》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103800428A (zh) * | 2012-11-15 | 2014-05-21 | 吉林吉春制药股份有限公司 | 一种治疗高血压病阴虚阳亢症以及冠心病的药物及其制备方法 |
CN107753522A (zh) * | 2017-10-24 | 2018-03-06 | 吉林农业科技学院 | 林蛙油包衣滴丸的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102697846B (zh) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101209274B (zh) | 雪莲提取物及其生产方法 | |
CN1247241C (zh) | 六味地黄滴丸 | |
CN102091111B (zh) | 雪莲巴布剂及其生产方法 | |
CN108272998A (zh) | 一种治疗失眠的蒙药复方制剂及其制备方法 | |
CN103599144B (zh) | 蜘蛛香环氧环烯醚萜酯有效部位的制备方法 | |
CN102697846B (zh) | 愈风宁心包衣滴丸及其制备方法 | |
CN102000147A (zh) | 一种防治高原反应及冠心病的药物配方及其制剂 | |
CN100563662C (zh) | 治疗心血管疾病的中药有效成分组合物及其制备方法 | |
CN103271978B (zh) | 一种用于抗缺氧、缺糖及治疗高原病的银杏叶复方制剂 | |
CN101278958A (zh) | 肺宁滴丸及其制备方法 | |
CN1857385B (zh) | 一种治疗颈椎病的药物组合物及其制备方法 | |
CN101444545A (zh) | 银杏叶滴丸及其制造方法 | |
CN101411735A (zh) | 一种防治冠心病的药物组合物的质量控制方法 | |
CN100358507C (zh) | 大规格六味地黄滴丸及其制备方法 | |
CN100375614C (zh) | 一种退黄保肝的舒肝宁滴丸及其制备方法 | |
CN104383547B (zh) | 天山雪莲提取物磷脂复合物、口腔崩解片及其制备方法 | |
CN101735189A (zh) | 小麦黄素的制备方法、制剂与用途 | |
CN102670698B (zh) | 千斤拔提取物在制备防治糖尿病药物中的应用 | |
CN102702061B (zh) | 一种盐酸水苏碱化合物及含有该化合物的药物组合物 | |
CN1322870C (zh) | 虎尾草黄酮胶囊的质量控制方法 | |
CN102389468B (zh) | 一种含甘木通冠心康制剂及其制备方法 | |
CN102772382A (zh) | 一种麦冬皂苷d滴丸及其制备方法 | |
CN106841464A (zh) | 一种杉寄生中鞣花酸和3,3`‑二甲氧基鞣花酸含量检测方法 | |
CN100358496C (zh) | 一种治疗脑炎、肝昏迷的醒脑静滴丸及其制备方法 | |
CN100486598C (zh) | 柴辛滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Yufengningxin coated dripping pill and preparation method thereof Effective date of registration: 20150128 Granted publication date: 20130828 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000078 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20150626 Granted publication date: 20130828 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2015990000078 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Yufengningxin coated dripping pill and preparation method thereof Effective date of registration: 20171207 Granted publication date: 20130828 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2017330000262 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190118 Granted publication date: 20130828 Pledgee: Bank of Communications Ltd Jinhua branch Pledgor: Zhejiang Jiafeng Pharmaceutical Co., Ltd. Registration number: 2017330000262 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |